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Abstract
Neurofibromatosis type 1 (NF1) is an autosomal dominantly inherited disorder, 
with an estimated prevalence of 1 in 3000–4000 people. Seizures occur 4–7% 
of individuals with NF1, mostly due to associated brain tumors or cortical mal-
formations. Seizures in NF1 are often relatively easy to control with one or more 
conventional antiseizure drugs; surgical resection of offending lesions is sometimes 
pursued. Surgery has been most successful for temporal lobe gliomas. However, if 
you faced the drug-resistant epilepsy you may consider the cortical malformations, 
tumors and hippocampal sclerosis. In this chapter, it is aimed to explain the types of 
seizures, EEG features and the properties of drug therapy in NF1.
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1. Introduction
Neurofibromatosis (NF-1) type 1, which is the most common neurocutaneous 
disease, is autosomal dominant inherited, and its incidence has been reported as 
1/3000 [1].
The NF-1 gene is located in the 17q11.2 region of chromosome 17, and this gene 
encodes a tumor suppressor protein called Neurofibromin. Neurofibromas are the most 
common tumors in NF1, often seen in adolescence and increasing in number and size 
with age. Most of them are benign and rarely undergo malignant transformation [2].
Diagnostic criteria for NF1 include cutaneous/subcutaneous or plexiform neurofi-
bromas, “cafe au lait” spots, axillary or inguinal freckles, Lisch nodules, optic glioma, 
and skeletal dysplasia. Cranial magnetic resonance imaging (MRI) can show focus 
areas of high T2-weighted signals known as neurofibromatosis bright objects (NBOS).
Other findings that may accompany NF1 include vasculopathy, short stature, 
malignancy tendency, macrocephaly, learning disability, and epilepsy. Other symp-
toms include cognitive dysfunction, pain in specific nerve distribution (usually 
due to the presence of neurofibroma), seizures, visual changes that may be associ-
ated with optic gliomas, stenosis of the major intracranial arteries leading to the 
Moyamoya phenomenon, headaches. The prevalence of epilepsy in NF1 is 4–5 times 
the prevalence defined in the general population and is reported to be 4–7% [3, 4].
2. Epilepsy mechanism at NF1
The exact mechanism of epilepsy in NF1 is not clear. Identifying the features 
associated with epilepsy can provide clues about its pathogenesis [5].
Neurofibromatosis
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Neurofibromin plays important roles in many aspects of cortical development, 
including synaptic plasticity, learning and memory, neurotransmitter phenotype, 
and synapse formation [6]. However, it is not clear why the brains of individu-
als with NF1 can be overstimulated and prone to seizures, and this issue is rarely 
discussed in the literature [7].
Figure 1. 
Potential mechanisms of increased epileptogenesis in NF1 [17]. Potential mechanisms of increased epileptogenesis 
in neurofibromatosis type 1. Protein neurofibromin is the NF1 gene product and functions as a negative regulator of 
Ras activity. In neurofibromatosis type 1, decreased neurofibromin levels lead to increased Ras activation and higher 
RAF/MEK/ERK and PI3K/AKT/mTOR signaling levels. Although the mechanism of increased seizures and epilepsy 
in patients with neurofibromatosis is unknown, changes in these signaling pathways may increase epileptogenesis, 
possibly through changes in GABAergic signaling, changes in ion channels, or altered synaptic plasticity.
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The possibilities are undoubtedly speculative and include the pathophysiological 
spectrum that disrupts the excitation and inhibition balance [8]. Possibly related 
to seizure mechanisms, GABA release and levels were found to increase in NF1 +/− 
mice, resulting in unlimited Extracellular Signal Regulated Kinase (ERK) signal and 
increased synaptic GABA release as a result of neurofibromin loss [9]. This finding 
explains the impaired cognition, learning, and Long-term potentiation (LTP) of 
NF1 +/− mice. However, decreasing rather than increasing GABA levels will be 
more consistent with susceptibility to epilepsy. However, the increased GABA 
release strategically limited to local inhibitory circuits could theoretically increase 
excitability [10].
In NF1 +/− mice, calcium channel opening increases in hippocampal neurons 
and calcium currents increase, which increases excitability and neurotransmitter 
release [11]. Dysfunction of various ion channels (e.g. sodium, potassium, cyclic 
nucleotide-gated, activated by hyperpolarization) has been reported in different 
brain regions and NF models, but no consistent model emerged to suggest a unified 
hypothesis about cortical hyper-excitability or seizures. Several sodium channel 
isoforms (NaV1.1, NaV1.7, NaV1.8) have increased expression and activity in NF1 
+/− mice, leading to hyper-excitability [12, 13].
These findings may be related to central neurons and circuits, a subject that 
needs to be investigated in terms of epilepsy mechanisms in NF. There is no 
published information on whether NF1 +/− mice alter the sensitivity to seizures 
induced by standard experimental methods (eg bicuculline, kindling) [14].
Stafstrom et al. stated that impaired excitation/inhibition balance and dysfunc-
tion of ion channels may be possible mechanisms of epilepsy in NF1 [15].
Neurofibromin deficiency leads to increased Ras activity, which is the mechani-
cal target of rapamycin activation, and GABAergic signaling in the inhibitory 
circuit, which may contribute to neuronal hyperpolarization. Neurofibromin also 
plays a role in cortical development including synaptogenesis and synaptic plastic-
ity; therefore, its deficiency may be associated with abnormal cortical development 
and seizure development (Figure 1) [15–17].
The high rate of learning disability in the epileptic group (without epilepsy;8,2 
with epilepsy; 64%) without any negative factors such as resistant epilepsy, multiple 
drugs or epileptic encephalopathy suggests that it is probably not caused by learning 
disability, but due to a GABA-mediated pathogenesis [17].
The mutation site in the NF1 locus may also be associated with epilepsy: rep-
lication of the NF1 locus has been shown to cause mental disability and epilepsy 
without any physical imprint of NF1. The duplication site also contains many genes 
that can cause epilepsy when the microdeletion site is deleted or mutated in some 
cases of NF1, explaining why only a small percentage of patients with NF1 experi-
ence seizures. Comparison of genotypes between NF1 patients with and without 
epilepsy may clarify this possibility [18].
3. Seizures in NF1
Neoplastic or non-neoplastic central nervous system symptoms occur in 15–20% 
of patients with NF-1. Brain lesions in NF1 have been reported as neoplastic, 
non-neoplastic structural changes, vasculopathy, cerebral and cerebellar cortical 
malformations [19].
Neoplastic lesions are classified as optic gliomas, brainstem gliomas, and other 
brain gliomas. Non-neoplastic structural lesions are NBOs, macrocephaly, corpus 
callosum pathologies, dural ectasia and encephalocele. In NF1, cortical malforma-
tions have been reported as transmantled cortical dysplasia, periventricular band 
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consisting of heterotopic gray matter with cerebral cortex pachygyria, and perisyl-
vian polymichrogyria [20, 21].
Describing five adult patients with epilepsy associated with aqueductal steno-
sis, subdural hematoma, cerebral hamartoma, and meningioma, Hsieh HY. et al. 
reported several NF1 patients with seizures caused by various tumor types. Most of 
these patients continued their follow-up without seizures after lesionectomy [22, 23].
It has been reported that the seizures of patients with hemimegalencephaly and 
NF1 are well controlled [24]. MRI lesions of other cortical developmental malfor-
mations such as focal cortical dysplasia and polymicrogyria are often accompanied 
by drug-resistant epilepsy [22, 25].
However, about half of NF1 patients with epilepsy do not have a structural 
abnormality on MRI [4] and it has been reported that MRI lesions in NF1 are not 
always localized with epileptiform discharges on EEG [16]. In this case, they raised 
the question of whether the genetic condition itself contributes to overstimula-
tion of the brain, susceptibility to seizures, and other chronic changes that lead to 
epilepsy. Seizures in NF1 are usually secondary to brain lesions such as tumors or 
cortical dysplasia [4, 26], but neurofibromatosis, a typical MRI lesion, has not been 
associated with bright nodes (NBOs) [4, 26].
NBOs (neurofibromatosis bright objects) were detected in 16 (69.6%) epilepsy 
patients and 108 (72.5%) patients without epilepsy in a study in which the MRI of 
172 (23 with and 149 without epilepsy) NF1 patients were examined. The loca-
tion or number of these intracranial lesions do not correlate significantly with the 
occurrence of epilepsy in our cohort. Among the 11 NF1 patients with intracranial 
tumors, 4 patients (36.36%) had seizures, whereas 19 (11.80%) of 161 NF1 patients 
without tumor were found to have seizures. In conclusion, in this article, epileptic 
seizure formation in NF1 patients was interpreted as associated with intracranial 
tumors, but not with NBOs [23].
Different seizure types and syndromes have been described in NF1. Most sei-
zures in NF1 tend to be focal-onset seizures and are generally secondary generalized 
[22, 27, 28]. The seizures in NF1 are thought to be caused by numerous focal lesions 
that make up the disorder, namely, tumors and malformations of cortical develop-
ment. The prevalence of West syndrome (infantile spasms) and febrile seizures is 
higher in NF1 patients compared to the general population.
EEGs are abnormal in about 25% of patients with NF1. EEG findings may 
include normal to focal or multifocal spike waves, spike and slow spike wave 
complexes at 2 Hz compatible with Lennox–Gastaut syndrome. The most common 
abnormality in EEG is focal disorders [27].
Therefore, seizure formation requires neuroimaging even if previous neuroim-
aging was normal. The relationship of NBOs to seizures is controversial, but most 
studies have concluded that NBOs are not associated with seizures [22, 28]. Seizures 
in NF1 are generally relatively easy to control with one or more conventional anti-
epileptic drugs (AED); Sometimes, those ending lesions are surgically resected. 
Surgery is the most successful for temporal lobe gliomas [3].
4. Epilepsy surgery in NF1
In the review of 43 studies, structural causes were found in half of the 
patients with NF1. Low-grade gliomas were the most common, followed by 
mesial temporal sclerosis, cortical growth malformation, dysembryoplastic 
neuroepithelial tumor, and cerebrovascular lesions. Surgical method was the 
best approach for the treatment of epilepsy in patients with NF1 with structural 
lesions [29].
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Eighteen patients with mesial temporal sclerosis (MTS) who were followed up 
with a diagnosis of NF1 and epilepsy have been reported in the literature. Ten of the 
18 patients were women and 8 were men, 10 patients had right MTS, 6 patients had 
left MTS and 1 patient had bilateral MTS [30].
Vivarelli et al. [22] described 9 patients with NF1 and brain lesions. 5 patients 
had cerebral tumor, 3 patients had cortical malformation and 1 patient had MTS. 
Responded to medication in 1 case with MTS [16].
Carmen Barba et al. [31] reported 12 resistant epilepsy patients with cortical 
development or malformations of glioneuronal tumors on NF1 and MRI. Four of 12 
patients had MTS. Four patients with MTS were women, and 3 had left MTS and 1 
had right MTS. Three of the 4 patients were seizure-free after temporal lobectomy.
In the study by Ostendorf AP. et al. [3] 9.5% of individuals with NF1 had a 
history of at least one unprovoked seizure and 6.5% were diagnosed with epilepsy. 
Individuals who had seizures were more likely to have inherited NF1 from their 
mothers. Focal seizures were the most common seizure type occurring in 57% of 
individuals [21]. It has been reported in the literature that 60% of individuals with 
NF1 have good seizure control with only one AED or without AED treatment [5, 16]. 
Epilepsy in NF1 can be associated with more than one type of epilepsy and syn-
dromes, and when relevant to localization, it is often drug resistant [31, 32].
5. Conclusion
As a result, epilepsy is more common in NF1 patients than in the general popula-
tion. Although the clinical features of epilepsy in NF1 are heterogeneous, most 
patients have focal seizures and have a good response to treatment. In at least half of 
cases, epilepsy is mainly caused by central nervous system structural lesions repre-
sented by brain tumors. However, other brain changes such as MTS, DNETs, cortical 
abnormalities, cerebrovascular disease, and other complications cannot be ruled 
out. In addition, epilepsy in NF1 is associated with a history of epilepsy and learning 
disabilities in a family that contributes to a genetic mechanism that may be associated 
with cellular or synaptic changes in the brain and epileptogenesis in the NF1 pan.
Given the heterogeneity of structural causes in NF1-, correlation of relevant 
epilepsy, clinical-video EEG and neuroimaging should always be performed, 
especially before surgery.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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